Scarica l'app Stockscreener
59.45
0.03%
0.02
Precedente Chiudi:
$59.43
Aprire:
$59.43
Volume 24 ore:
1.14M
Relative Volume:
0.41
Capitalizzazione di mercato:
$11.42B
Reddito:
$2.95B
Utile/perdita netta:
$523.88M
Rapporto P/E:
22.10
EPS:
2.69
Flusso di cassa netto:
$620.18M
1 W Prestazione:
-0.83%
1M Prestazione:
+10.32%
6M Prestazione:
+3.99%
1 anno Prestazione:
-10.59%
Intervallo 1D:
$58.89
$59.82
Intervallo di 1 settimana:
$58.44
$60.58
Portata 52W:
$50.76
$73.51
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
Nome
Biomarin Pharmaceutical Inc
Settore
Industria
Telefono
(415) 506-6700
Indirizzo
105 DIGITAL DRIVE, NOVATO, CA
Confronta BMRN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
59.45 | 11.42B | 2.95B | 523.88M | 620.18M | 2.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-03 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-11-06 | Downgrade | Stifel | Buy → Hold |
| 2025-09-08 | Iniziato | H.C. Wainwright | Neutral |
| 2025-09-03 | Iniziato | Raymond James | Outperform |
| 2025-07-03 | Ripresa | Morgan Stanley | Overweight |
| 2025-02-24 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-10-30 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-08-20 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2024-05-17 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-05-14 | Iniziato | Evercore ISI | Outperform |
| 2023-11-15 | Iniziato | Wells Fargo | Overweight |
| 2023-10-23 | Aggiornamento | Bernstein | Underperform → Mkt Perform |
| 2023-09-28 | Iniziato | Raymond James | Mkt Perform |
| 2023-09-18 | Iniziato | UBS | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Perform |
| 2023-07-05 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-06-14 | Ripresa | Credit Suisse | Outperform |
| 2023-03-21 | Iniziato | Bernstein | Underperform |
| 2023-02-22 | Downgrade | Oppenheimer | Outperform → Perform |
| 2023-02-21 | Iniziato | Citigroup | Neutral |
| 2023-01-30 | Iniziato | BMO Capital Markets | Market Perform |
| 2023-01-18 | Iniziato | Canaccord Genuity | Hold |
| 2022-10-31 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-06-13 | Ripresa | Wedbush | Neutral |
| 2022-04-25 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-11-22 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2021-10-07 | Ripresa | Jefferies | Buy |
| 2021-09-09 | Aggiornamento | Stifel | Hold → Buy |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-03-04 | Ripresa | Guggenheim | Buy |
| 2021-03-01 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2020-08-20 | Downgrade | Citigroup | Buy → Neutral |
| 2020-08-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2020-08-19 | Downgrade | Evercore ISI | Outperform → In-line |
| 2020-08-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-08-19 | Downgrade | Stifel | Buy → Hold |
| 2020-07-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-06 | Reiterato | Citigroup | Buy |
| 2020-01-28 | Iniziato | BMO Capital Markets | Market Perform |
| 2020-01-27 | Iniziato | BMO Capital Markets | Market Perform |
| 2020-01-24 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-11-27 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-05-23 | Ripresa | Citigroup | Buy |
| 2019-04-09 | Ripresa | Raymond James | Outperform |
| 2019-01-02 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2018-12-14 | Iniziato | Wolfe Research | Outperform |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-08-07 | Reiterato | Stifel | Buy |
| 2018-08-03 | Reiterato | Stifel | Buy |
Mostra tutto
Biomarin Pharmaceutical Inc Borsa (BMRN) Ultime notizie
Investor Mood: How BioMarin Pharmaceutical Inc stock performs in weak economyJuly 2025 Pullbacks & Safe Entry Trade Reports - moha.gov.vn
BioMarin’s $4.8 Billion Amicus Acquisition: A Strategic Pivot to Rare Disease Dominance - FinancialContent
These nine Bay Area drug makers are hurtling toward key FDA approval decisions in 2026 - The Business Journals
VIRGINIA RETIREMENT SYSTEMS ET Al Reduces Stock Position in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
HC Wainwright: BioMarin’s (BMRN) Amicus acquisition stabilizes cash flow while Voxzogo remains near-term driver - MSN
H.C. Wainwright: BioMarin’s (BMRN) Amicus Acquisition Stabilizes Cash Flow While Voxzogo Remains Near-Term Driver - Insider Monkey
H.C. Wainwright: BioMarin's (BMRN) Amicus Acquisition Stabilizes Cash Flow While Voxzogo Remains Near-Term Driver - Finviz
12 Best NASDAQ Stocks to Buy in 2026 - Insider Monkey
BioMarin Acquiring Amicus — Both Great Companies, Only One Worth Buying Now (NASDAQ:BMRN) - Seeking Alpha
Is BioMarin Pharmaceutical Inc. (BMRN) the Ridiculously Cheap Stock to Buy Now? - Finviz
Cwm LLC Has $8.90 Million Stock Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
BioCentury’s 2025-26 picks and predictions. Plus: BioMarin and more biotech ICYMI — a BioCentury podcast - BioCentury
Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal - FinancialContent
BioMarin ends development of BMN 349 AATD therapy - MSN
BioMarin to Acquire Amicus Therapeutics for $4.8B - Contract Pharma
Rocket Lab, Micron, And CoreWeave Are Among the Top 10 Large-Cap Gainers Last Week (Dec. 22-Dec. 26): Are the Others in Your Portfolio?Astera Labs (NASDAQ:ALAB), BioMarin Pharmaceutical (NASDAQ:BMRN), Ciena (NYSE:CIEN), CoreWeave (NA - Benzinga
Portfolio Update: How BioMarin Pharmaceutical Inc stock performs in weak economy2025 Earnings Impact & Long-Term Investment Growth Plans - moha.gov.vn
Rice Hall James & Associates LLC Boosts Stock Position in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin Pharmaceutical Inc. $BMRN Shares Acquired by Pacer Advisors Inc. - MarketBeat
BioMarin Pharmaceuticals: Amicus Transforms Business Case Overnight (NASDAQ:BMRN) - Seeking Alpha
Weekly Buzz: FDA OKs Roche's Lunsumio VELO; It's No For Tolbrutinib; BioMarin, SNY Open Wallets - RTTNews
Swedbank AB Buys 35,000 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin names new chief accounting officer - MSN
Silver Breaks Above $70, Novo Nordisk Soars 9% On Obesity Pill Approval: What's Moving Markets Tuesday? (CORRECTED) - Benzinga
Silver Tops $70, Novo Nordisk Soars 9% On Obesity Pill ApprovalBullish (NYSE:BLSH), BioMarin Pharmaceutical (NASDAQ:BMRN) - Benzinga
BioMarin to Acquire Amicus Therapeutics for $4.8 Billion - New Jersey Business Magazine
BioMarin Pharmaceutical (BMRN) Stock Is Up, What You Need To Know - Finviz
What's Going On With BioMarin Stock On Tuesday? - Sahm
BioMarin Pharmaceutical (NASDAQ:BMRN) Trading 3.9% Higher on Analyst Upgrade - MarketBeat
BioMarin Pharmaceutical (NASDAQ:BMRN) Given New $100.00 Price Target at Truist Financial - MarketBeat
Analysts Grow More Bullish on BioMarin Pharmaceuticals Inc. (BMRN) After Amicus Acquisition - Finviz
Analysts grow more bullish on BioMarin Pharmaceuticals Inc. (BMRN) after Amicus acquisition - MSN
Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), Lexicon Pharmaceuticals (LXRX) and Pfizer (PFE) - The Globe and Mail
Narrow-Moat BioMarin's $4.8 Billion Deal for Amicus Therapeutics Expands Rare Disease Portfolio - Morningstar
Analysts Have Conflicting Sentiments on These Healthcare Companies: AbbVie (ABBV), Disc Medicine (IRON) and BioMarin Pharmaceutical (BMRN) - The Globe and Mail
BioMarin (BMRN) Stock News Today: Amicus Acquisition Fallout, BMN 349 Cut, and Fresh Wall Street Price Targets (Dec. 22, 2025) - ts2.tech
American biotech company BioMarin acquires Amicus Therapeutics for $4.8 billion - AKM.RU
BioMarin: Amicus Buyout Sparks My Enthusiasm (NASDAQ:BMRN) - Seeking Alpha
BioMarin to Buy Rare Disease Drugmaker Amicus Therapeutics for $4.8B - sharewise.com
7 Most Promising Gene Editing Stocks According to Analysts - Insider Monkey
BioMarin snaps up Amicus Therapeutics for $4.8bn amid rare disease push - Pharmaceutical Technology
BioMarin quietly discards liver disease candidate after $4.8B Amicus announcement - Fierce Biotech
BioMarin stock price target raised to $100 from $80 at Truist Securities - Investing.com UK
BioMarin stock price target raised to $100 from $80 at Truist Securities By Investing.com - Investing.com Australia
BioMarin drops development of liver, lung disease asset - Seeking Alpha
Truist Securities Lifts BioMarin Pharmaceutical Price Target to $100 From $80, Maintains Buy Rating - marketscreener.com
BioMarin ends development of BMN 349 for AATD liver disease - Investing.com
BioMarin Ends Development of BMN 349 AATD Therapy - TipRanks
BioMarin stock price target raised to $60 from $55 at H.C. Wainwright By Investing.com - Investing.com South Africa
BioMarin ends development of BMN 349 for AATD liver disease By Investing.com - Investing.com UK
Biomarin Pharmaceutical Inc Azioni (BMRN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):